187 related articles for article (PubMed ID: 9915408)
21. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
23. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
24. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
McDermott DF
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
[TBL] [Abstract][Full Text] [Related]
25. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.
Fallick ML; McDermott DF; LaRock D; Long JP; Atkins MB
J Urol; 1997 Nov; 158(5):1691-5. PubMed ID: 9334580
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
27. [Current status of treatment of renal cell carcinoma and future problems].
Satomi Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):1-13. PubMed ID: 1689406
[TBL] [Abstract][Full Text] [Related]
28. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
29. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
31. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma.
Vermassen T; De Meulenaere A; Van de Walle M; Rottey S
Acta Clin Belg; 2017 Feb; 72(1):12-18. PubMed ID: 27356035
[TBL] [Abstract][Full Text] [Related]
34. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
Bukowski RM
Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
[TBL] [Abstract][Full Text] [Related]
35. [Adenocarcinoma of the kidney (hypernephroma)].
Probst W; Joss R; Triller J; Schönenberger A; Greiner R; Brunner KW
Schweiz Med Wochenschr; 1984 Oct; 114(41):1406-15. PubMed ID: 6208605
[TBL] [Abstract][Full Text] [Related]
36. Multimodal treatment of advanced renal cancer in 2017.
Mennitto A; Verzoni E; Grassi P; Ratta R; Fucà G; Procopio G
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1395-1402. PubMed ID: 28956645
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy and gene therapy.
Gitlitz BJ; Belldegrun A; Figlin RA
Semin Urol Oncol; 1996 Nov; 14(4):237-43. PubMed ID: 8946624
[TBL] [Abstract][Full Text] [Related]
38. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
39. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
Pandha H
Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
[No Abstract] [Full Text] [Related]
40. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
